- Case Study
- Open Access
A case of leprosy in Malawi. Making the final push towards eradication: a clinical and public health perspective
© The Author(s). 2016
- Received: 7 August 2015
- Accepted: 20 July 2016
- Published: 2 September 2016
Statistically speaking, Malawi has achieved the World Health Organisation's target for the elimination of leprosy (<1 case per 10 000 people), yet the disease is still considered a leading cause of long term physical disability. In this case study the authors discuss the presentation of a 39-year-old gentleman to a district hospital in Malawi with multibacillary, lepromatous leprosy. The condition was initially managed in the community as an ‘allergy’ which suggests that local barriers currently hinder the detection of leprosy in this developing primary care system. Leprosy is a multi-system disease and this gentleman demonstrated evidence of lepromatous orchitis. Promoting an awareness of these systemic manifestations will increase the the detection of complications and circumvent long term morbidity. Efforts to optimise systems of detection, management and public and professional education are essential to drive eradication in these at-risk populations. At an international level, we must strive to fulfil the objectives outlined by the ‘Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy for 2011–2015’. At a national level, local research should delineate community factors that impede the eradication of leprosy. Developing new diagnostic and epidemiologic tools, more efficacious chemoprophylactic regimens and vaccination for endemic regions would facilitate these efforts.
- World Health Organisation
- International complication
- Communicable disease
Please see Additional file 1 for translations of the abstract into the six official working languages of the United Nations.
Leprosy has been endemic in many regions of the world since biblical times. In 2014, 213 899 new cases were detected worldwide . Mycobacterium leprae (M. leprae) is transmitted following prolonged close contact with infected patients. The bacilli reside within upper airway secretions and spread through the expulsion and consequent inhalation of airbourne droplets. Although highly contagious, the clinical disease only develops in genetically susceptible individuals. The quality of the immune response determines the outcome of infection. Ridley and Jopling characterised a spectrum based on clinical, histological and immunological variables. They defined three broad syndromes: tuberculoid, borderline and lepromatous leprosy [2, 3]. The latter develops when CD4+ T cells preferentially polarise to a T helper 2 response. This promotes humoral immunity which fails to clear the intracellular bacilli. Leprosy is characterised by a remarkably long incubation period spanning between six months and twenty years . Lepromatous lesions are characterised by deteriorating sensitivity to heat, pain and tactile sensation as the peripheral nerves denervate. Multiple large plaques develop symmetrically over colder areas of the body. They are hypochromic, erythematous and have indefinite borders. Over time, some of these plaques form nodules, known as lepromas. Borderline cases develop hypochromic spots with slight insensitivity whilst tuberculoid leprosy is characterised by a few isolated erythematous plaques.
The WHO diagnostic features for leprosy
World Health Organisation operational diagnostic criteria for leprosy
1. Skin lesion consistent with leprosy and with definite sensory loss, with or without thickened nerves
2. Positive skin smears
In all settings, a detailed travel, social and contact history can accurately predict the risk of exposure. Moet et al. showed that the most important determinants of clinical disease include i) the intensity of contact and ii) inherited susceptibility including HLA-DR2 and non-HLA polymorphism e.g. in TNF-α . Seropositivity represents a 20-fold increased risk of developing clinical leprosy [7, 8] whilst the bacterial load, as measured by a skin smear can predict the transmission risk . Differential diagnoses for multibacillary lepromatous skin lesions include scleroderma, mycosis fungoides, pellagra, asteatosis, ichtyosis and eczema or contact dermatitis. The primary neurological symptoms resemble common mononeuropathies. Where there is systemic involvement, clinicians should consider systemic lupus erythematosus, rheumatoid arthritis, dermatopolymyositis and systemic vasculitis.
Ideally, leprosy should be confirmed by the presence of acid-fast bacilli in skin biopsies or split skin smears. M. Leprae is a gram variable organism and can be decolourised by a Ziehl-Neelsen stain thus a modified Fite stain should be used. Skin biopsies should be taken from the centre of skin plaques or nodules in lepromatous leprosy and the periphery of tuberculoid lesions. Despite being a major referral centre, this district hospital did not have the laboratory facilities to perform split skin smears or skin biopsies. Whilst the WHO standard diagnostic criteria state that these investigations are not required to make a formal diagnosis (Table 1), this situation highlights the inadequacy of laboratory provisions in the Lilongwe health district. To achieve eradication targets, these secondary care institutions require access to reliable, definitive laboratory investigations. Boyce et al. demonstrate that strategies to improve investment at a national and district level are a cost-effective means of increasing detection rates, reducing misdiagnosis and improving the follow up of treatment .
Systems with a significant degree of M. Leprae infiltration and/or dysfunction
Secondary amyloidosis can develop in several organs although it commonly causes kidney damage by glomerulonephritis (incidence up to 50 %), interstitial nephritis, nephrotic syndrome, pyelonephritis and acute tubular necrosis.
M. leprae can infiltrate the upper respiratory tract including the nose, pharynx, larynx, epiglottis and trachea. Common symptoms include cough, hoarseness, and, occasionally, dyspnoea. The bronchi and lungs are usually spared.
Leprosy (particularly multibacillary) has been associated with arrhythmias, dyspnoea, ventricular hypertrophy and ST segment abnormalities. M. Leprae can invade the cardiac autonomic system. Coronary artery disease and arteriographic abnormalities affect approximately 11 and 50 % of patients respectively.
Approximately 90 % of men develop orchitis, commonly with involvement of the epididymis. This can lead to infertility, sexual impotence and gynaecomastia. Approximately 30 % of patients develop cortical adrenal lesions.
The incidence of liver involvement is estimated at between 48 % and almost 100 %. Lepromatous hepatitis describes portal and centrolobular granulomas, and fibrosis with acid-fast bacilli. Infrequently, secondary amyloidosis can cause hepatic damage. The gall bladder, biliary system and pancreas are usually spared.
90 % of lepromatous patients show bacillaemia. Bone marrow infiltration can lead to pancytopaenia. A widespread lymphadenopathy can also occur.
Approximately 90 % of infected males develop orchitis. Foamy macrophages often form granulomas which replace the testicular parenchyma. Otherwise, parenchymal fibrosis and hyalinization of the spermatopoietic tubules may occur. If left untreated this will eventually cause testicular atrophy and infertility. There is very little involvement of the female genital tract.
Public health perspective
The WHO’s ‘Strategic Plan for Leprosy Elimination 2000–2005’ made a commitment to eliminate leprosy through control measures that are accessible at all local health facilities . These control measures emphasised facilities to diagnose and treat patients with multidrug chemotherapy, patient and family counselling, community education, disability support, rehabilitation and referrals for complications. In some nations, the uptake of these strategies was slow and in 2006, the WHO published a revised plan; ‘The Global Strategy for Further Reducing the Leprosy Burden and Sustaining Leprosy Control Activities 2006–2010’ . This focused on ‘morbidity control’ to further promote the timely detection of new cases, their treatment with effective multidrug chemotherapy, the prevention of disability and rehabilitation. The strategy emphasised equitable resource distribution and the provision of affordable and easily accessible care. Leprosy has long been a source of stigma thus socio-educational programmes were prioritised to dispel fear and motivate individuals to seek treatment.
Leprosy is a leading communicable cause of neurological disability throughout the globe . As with this gentleman, ensuring timely diagnosis and treatment is the most effective way of mitigating damage to the sensory, motor and autonomic function of peripheral nerves. The WHO definition of Grade 2 disability (G2D) has been proposed as a more robust indicator of international progress than leprosy prevalence because it is less susceptible to operational factors such as treatment duration and case-finding methodology. In 2012 Msyamboza showed that 21 % of patients in their community-based cross sectional study in Malawi had a G2D . The Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy for 2011–2015, set a target to reduce new cases of leprosy with G2D per 100 000 total population by 35 % relative to 2010. Looking forward, their aim is to reduce the burden to 1 new G2D case per one million population by 2020 . However, a criticism of the indicator is that such a neurological assessment may be too complex for some developing settings, especially for clinicians that haven’t received specific training and have no means of monitoring local prevalence .
The WHO has defined the elimination of leprosy as a ‘national prevalence of less than 1 case per 10 000 population’ . Malawi fulfils this criteria, however Msyamboza et al. showed that between 2006 and 2011, the prevalence and detection rates actually increased . Furthermore, cure rates for paucibacillary (1–5 lesions) and multibacillary (>5 lesions) leprosy were 63 and 33 % respectively; substantially below the expected 80 % . This gentleman was misdiagnosed at the community health centre which indicates that despite global initiatives, cases of lepromatous leprosy are still missed in this region of Malawi. Attributable factors may include a lack of decentralisation to health centres for diagnosis and treatment, insufficient knowledge and skills of health centre staff, poor registration and recording systems, and a lack of political commitment by government and health partners . However, to our knowledge there are no recent studies investigating these potential issues in Malawi. In addition to global efforts, individualised, national systems of detection, contact tracing and the provision of affordable treatments are needed to definitively eradicate leprosy in these settings .
➢ Leprosy is still a prevalent communicable disease and a leading cause of long term physical disability even in countries that have statistically achieved the WHO elimination target
➢ Clinicians must consider leprosy in those with a significant contact history and be aware that leprosy can lead to severe multi-system sequelae
➢ Wider accessibility to clinical laboratories equipped with the resources to confirm leprosy could improve detection and cure rates, reduce misdiagnosis and unnecessary treatment and enhance patient follow-up.
➢ Further research is needed to develop and implement national strategies to address local factors influencing the detection and management of lepromatous disease
The authors would like to acknowledge the staff at Nkhoma Hospital for their kind personal and professional support during our time in Malawi.
The gentleman described in this case report was seen by both authors. The corresponding author conceived and produced the initial manuscript. Both authors made valuable contributions throughout and were heavily involved in the production of the final manuscript. Both authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Ethics approval and consent to participate
We obtained informed consent from the patient for the specific purpose of using his clinical details and photographs for the publication of a case study in a research journal and for educating health professionals. Confidential personal details have been removed and the photographs have been modified to ensure full anonymity.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Global leprosy update, 2013. reducing disease burden. Wkly Epidemiol Rec. 2015;90(36):461–76.Google Scholar
- Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255–73.PubMedGoogle Scholar
- Ridley DS, Jopling WH. A classification of leprosy for research purposes. Lepr Rev. 1962;33:119–28.PubMedGoogle Scholar
- Lastoria JC, Abreu MA. Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - part 1. An Bras Dermatol. 2014;89(2):205–18.View ArticlePubMedPubMed CentralGoogle Scholar
- WHO. Diagnosis of leprosy. 2015; http://www.who.int/lep/diagnosis/en/. Accessed 10 June 2015.
- Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. Lepr Rev. 2004;75(4):310–26.PubMedGoogle Scholar
- Ulrich M, Smith PG, Sampson C, et al. IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Int J Lepr Other Mycobact Dis. 1991;59(3):405–15.PubMedGoogle Scholar
- Douglas JT, Celona RV, Abalos RM, Madarang MG, Fajardo T. Serological reactivity and early detection of leprosy among contacts of lepromatous patients in Cebu, the Philippines. Int J Lepr Other Mycobact Dis. 1987;55(4):718–21.PubMedGoogle Scholar
- Boyce SP, Berruti Andrés A, Connolly H, Schneidman M. Evaluating the Economic and Health Impacts of Investing in Laboratories in East Africa: Development and Application of a Conceptual Framework. Washington: Health, Nutrition and Population (HNP) Discussion Paper Series; 2015.Google Scholar
- WHO. The final push towards elimination of leprosy: strategic plan 2000–2005. Geneva: WHO; 2000.Google Scholar
- WHO. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006–2010. Geneva: WHO; 2006.Google Scholar
- Lockwood DN. Leprosy elimination-a virtual phenomenon or a reality? BMJ. 2002;324(7352):1516–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Msyamboza KP, Mawaya LR, Kubwalo HW, et al. Burden of leprosy in Malawi: community camp-based cross-sectional study. BMC Int Health Human Rights. 2012;12:12–2. 08/0602/26/received07/31/accepted.Google Scholar
- WHO. Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy for 2011–2015. New Delhi: WHO; 2009.Google Scholar
- Neurology in sub-Saharan Africa--WHO cares? Lancet Neurol. 2006;5(8):637.Google Scholar
- WHO. Leprosy elimination. 2015; http://www.who.int/lep/en/. Accessed 10 June 2015.
- Smith CS, Noordeen SK, Richardus JH, et al. A strategy to halt leprosy transmission. Lancet Infect Dis. 2014;14(2):96–8.View ArticlePubMedGoogle Scholar
- Klioze AM, Ramos-Caro FA. Visceral leprosy. Int J Dermatol. 2000;39(9):641–58.View ArticlePubMedGoogle Scholar
- de Abreu MA, Michalany NS, Weckx LL, Neto Pimentel DR, Hirata CH, de Avelar Alchorne MM. The oral mucosa in leprosy: a clinical and histopathological study. Braz J Otorhinolaryngol. 2006;72(3):312–6.View ArticlePubMedGoogle Scholar
- Liu TC, Qiu JS. Pathological findings on peripheral nerves, lymph nodes, and visceral organs of leprosy. Int J Lepr Other Mycobact Dis. 1984;52(3):377–83.PubMedGoogle Scholar
- Desikan KV, Job CK. A review of postmortem findings in 37 cases of leprosy. Int J Lepr Other Mycobact Dis. 1968;36(1):32–44.PubMedGoogle Scholar
- Agarwal SC, Maheshwari HB, Mittal MM, Kumar S. A histological study of liver lesions in leprosy. Indian J Med Res. 1973;61(3):389–95.PubMedGoogle Scholar